Virax Biolabs Group Ltd - Class A VRAX

NAS: VRAX | ISIN: KYG9495L1251 30/05/2025

0,963 USD (+0,47%)

(+0,47%) 30/05/2025

Grafiek Virax Biolabs Group Ltd - Class A

Grafiek Virax Biolabs Group Ltd - Class A

1 dag1d 0,47%
1 week1w -8,33%
1 maand1m -1,79%
3 maanden3m -39,47%
6 maanden6m -50,64%
1 jaar1j -7,45%
5 jaar5j -99,47%

Virax Biolabs Group Ltd - Class A in het nieuws

Toon enkel gratis nieuws

18 maart 2025 · Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes · Persbericht

13 maart 2025 · Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting · Persbericht

5 maart 2025 · Virax Biolabs to Present at 19th World Immune Regulation Meeting · Persbericht

9 september 2024 · Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference · Persbericht

29 augustus 2024 · Virax Biolabs to Participate at 7th European Congress of Immunology · Persbericht

28 augustus 2024 · Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East · Persbericht

23 augustus 2024 · Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares · Persbericht

22 augustus 2024 · Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares · Persbericht

25 april 2024 · Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 · Persbericht

16 april 2024 · Virax Biolabs to Participate at ESCMID Global 2024 · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe